cyrilzakka/clinical-trials huggingface dataset:
Colorectal Cancer Awareness in Turkey

Colorectal cancer is among the most common types of cancer worldwide. Population-based screening programs for breast, cervical, and colorectal cancer have been introduced as part of cancer control in many high-income countries. Population-based cancer screening programs do not exist in most low- and middle-income countries. There are some studies that report the awareness of colorectal cancer in Turkey.

Colorectal cancer is the third most common type of cancer in both men and women. According to World Health Organization data, in 2012, 694 thousand people were thought to be due to colorectal cancer and this number increased to 862 thousand people in 2018. Especially in most low- and middle-income countries where cancers are mainly detected through very-late-stage symptoms and many are not reported. Recent researches may lead to new approaches to early detection and treatment using improved awareness of the symptomatic disease and population-based screening of asymptomatic people. The increasing of colorectal cancer awareness could help early detection of colorectal cancers. In this study, the investigators aimed to determine the level of awareness of colorectal cancer and knowledge about colorectal cancer screenings in patients who applied to general surgery outpatients clinic where a colorectal cancer diagnosis was most frequently diagnosed.

Eligibility Criteria:
Inclusion Criteria:

* Patients who apply to the general surgery outpatients clinic

Exclusion Criteria:

* Younger than 18 years old
* Older than 80 years old
* Mental retardation or other mental illness
* Refusing to join the study
Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects

This is a randomized, open-label study to evaluate the safety/tolerability and PK/PD drug-drug interactions between DWP14012 and aspirin when administered in combination.


Eligibility Criteria:
Inclusion Criteria:

* Healthy adults aged ≥ 19 and ≤ 50 years at screening
* Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening

  ※ BMI (kg/m2) = body weight (kg)/\[height (m)\]2
* Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information
* Subjects who are eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, and investigator questioning, etc.
* For women, negative urine pregnancy test (hCG) at the screening visit

Exclusion Criteria:

* Subjects with hypersensitivity or history of clinically significant hypersensitivity to drugs including potassium competitive acid blocker \[P-CAB\] class, aspirin, salicylic acid, or other drugs (non-steroidal anti-inflammatory drug \[NSAIDs\], antibiotics, etc.)
* Women who are or may be pregnant, or are breast-feeding
* Subjects with a history related to blood clotting disorder or bleeding
* Subjects with a medical diagnosis of functional constipation
* Subjects with a history of drug abuse or a positive result of using abusive drugs in the urine drug screen
* Subjects who participated in other clinical trials (including bioequivalence studies) within 6 months prior to the first scheduled dose of the IP
* Subjects who donated whole blood within 2 months, donated blood components within 1 month, or received blood transfusion within 1 month prior to the first scheduled dose
* Subjects who are unable to refrain from grapefruit-containing products from 3 days prior to the first scheduled dose until last discharge from hospital
* Subjects or their spouses or partners who are unable to use medically acceptable appropriate double-method of contraception or medically acceptable contraception throughout the study period and for at least 4 weeks after the last IP administration, and disagreed to refrain from donating sperms during this period
* Subjects with hereditary disorders including galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc.
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity

The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.

Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure. There are drugs which may protect against cardiotoxic effects of anthracyclines (renin-angiotensin inhibitors and beta blockers), but they are not tolerated due to hypotension. Ivabradine is heart rate lowering drug without effect on blood pressure which was approved for treatment of angina pectoris and heart failure. The aim of this study is to investigate protective effects of ivabradine in cancer patients undergoing anthracycline-based chemotherapy.

Ivabradine selectively inhibits If currents in the sinus node and prolongs the duration of spontaneous depolarization. That controls the heart's contractions and regulates the heart rate. Additionally, ivabradine might preserve myocardial function and contractility without effect on blood pressure. Ivabradine was approved for symptomatic treatment of chronic stable angina pectoris and chronic heart failure.

The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* cancer patients undergoing anthracyclines based chemotherapy;
* heart rate (HR) \> 70 times per minute;
* Written informed consent.

Exclusion Criteria:

* Contraindications for ivabradine administration;
* HR\<70 times per minute;
* Incapability to complete informed consent;
* Severe valve disease;
* Left ventricular ejection fraction (LVEF)≤ 30 %;
* Other severe conditions;
* Poor echogenicity.
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.

This single arm study will assess the efficacy and safety of combination first-line treatment with docetaxel + Xeloda + Avastin in patients with inflammatory or locally advanced breast cancer. Patients will receive 3-weekly cycles of Avastin (15mg/kg i.v. on day 1 of each cycle), docetaxel (75mg/m2 i.v. on day 1 of each cycle, after Avastin) and Xeloda (2000mg/m2 p.o. on days 1-15 of each cycle). Four cycles of chemotherapy are planned, plus an optional additional two cycles; after chemotherapy patients will be assessed for surgery. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility Criteria:
Inclusion Criteria:

* female patients, \>=18 years of age;
* HER2-negative, locally advanced (stage II or III) or inflammatory cancer of the breast;
* ECOG performance status 0-1.

Exclusion Criteria:

* metastatic disease (stage IV);
* previous treatment for breast cancer;
* evidence of CNS metastasis;
* current or recent (within 10 days of first dose of Avastin) use of aspirin (\>325mg/day) NSAIDs or full dose anticoagulants for therapeutic purposes;
* clinically significant cardiovascular disease.
Comparison Of Dexmedetomidine & Ketamine For Control Of Shivering In Vaginal Hysterectomy Under Spinal Anesthesia

comparison of Dexmedetomidine And Ketamine For Control Of Shivering In Vaginal Hysterectomy Proceeded Under Spinal Anesthesia.

In this study the participants aim to Compare Dexmedetomidine And Ketamine For Control Of Shivering In Vaginal Hysterectomy Proceeded Under Spinal Anesthesia regarding efficacy, hamemodynamic stability, outcomes and adverse effects.

Eligibility Criteria:
Inclusion Criteria:

1. Patients of age 45-55 years requiring vaginal hysterectomy
2. American Society of Anesthesiology (ASA) of Grade I-II

Exclusion Criteria:

1. Patients unwilling or non-cooperative for spinal anesthesia
2. Patients with uncontrolled hypertension, vascular or coronary disease,
3. patients with increased intraocular or intracranial pressure
4. Patients with known bleeding and psychiatric disorders
5. Patients taking anti platelets drugs.
A Study of Zanubrutinib in Patients With ITP

This project was undertaken to evaluate the efficacy and safety of BTK inhibitor Zanubrutinib for the secondary treatment of adults with primary immune thrombocytopenia (ITP).

The investigators are undertaking a prospective trial of 10 adults with ITP in China. Zanubrutinib is administered as 80 mg po. qd for 6 weeks. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed primary refractory ITP
* Platelet counts \<30×10\^9/L or with bleeding symptoms
* Willing and able to sign written informed consent

Exclusion Criteria:

* Secondary thrombocytopenia
* Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit
* HIV infection or hepatitis B virus or hepatitis C virus infections
* Malignancy
* Severe medical condition (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia)
* Nursing or pregnant patients
* Patients who are deemed unsuitable for the study by the investigator
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of B-cell lymphoma (BCL) as: (1) histologically documented lymphomas expected to express CD19 and CD20, including Grades 1 to 3B follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), transformed indolent non-Hodgkin lymphoma (tNHL), diffuse large B-cell lymphoma (DLBCL) \[not otherwise specified\], high-grade BCL, primary mediastinal BCL, and Richter transformation (RT; expansion part of study only); (2) R/R disease following at least 1 prior systemic regimen containing an anti-CD20 monoclonal antibody (mAb) for which the participant has no available curative treatment options; and (3) evaluable F-fluorodeoxyglucose (FDG)-avid disease, or measurable disease defined by at least one bi dimensionally measurable lesion
* Male participants and female participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception

Exclusion Criteria:

* Females who are pregnant or breastfeeding
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2
* Body weight \<50 kg
* Evidence of insufficient organ function
* Receipt of any biological therapy, chemotherapy (except for rituximab), or any investigational therapy within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or localized radiation therapy to a target lesion within 14 days prior to Day 1
* Currently receiving or likely to require systemic immunosuppressive therapy, e.g., prednisone \>5 mg daily, for any reason from Day -5 to Day 29, with the exception of corticosteroids as a pre medication required for conditioning chemotherapy or rituximab
* Prior allogeneic hematopoietic stem cell transplant (HSCT) or allogeneic chimeric antigen receptor (CAR) T-cell therapy within 6 months of Day 1, or ongoing requirement for systemic graft-versus-host disease (GvHD) therapy
* Receipt of an allograft organ transplant
* Non-malignant central nervous system (CNS) disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment
* Clinically significant cardiovascular disease
* Clinically significant infections
* Receipt of a live vaccine \<6 weeks prior to start of study intervention
* Known allergy to human albumin or DMSO
* Any medical condition or clinical laboratory abnormality that per investigator or medical monitor judgement, precludes safe participation in and completion of the study, or that could affect compliance with protocol conduct or interpretation of results
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).


Eligibility Criteria:
Inclusion Criteria:

* Patients being treated with Darbepoetin alfa.

Exclusion Criteria:

* Patients having complication or history of a cardiovascular / lung / brain infarction.
* Patients having a pronounced hemorrhagic lesion.
Obesity, PEEP and Postoperative Oxygenation

A study on overweight patients undergoing anesthesia for laparoscopic surgery.

- evaluation of positive end-expiratory pressure versus zero positive end-expiratory pressure during awakening on oxygenation in the early postoperative period.

Positive end-expiratory pressure (PEEP) is often used during mechanical ventilation to preserve end-expiratory lung volume. After emergence and extubation, this volume will diminish instantly. Some patients will have difficulties to restore functional residual capacity (FRC) during the early phase of recovery. If routine high FIO2 is being delivered together with maintained PEEP prior to extubation, several important prerequisites are established for the development of postoperative atelectasis. The investigators hypothesize that establishing zero positive end-expiratory pressure (ZEEP) immediately prior to emergence preoxygenation, will prevent gas with high oxygen concentration from entering dorso-basal areas of the lungs, and thereby diminishing postoperative atelectasis formation and improve oxygenation.

This randomized controlled study will study overweight patients undergoing general anesthesia for laparoscopic surgery. The patients in the two study groups will receive mechanical ventilation with identical settings, comprising low TV, PEEP, and no RM. Randomization will occur at the end of surgery, before awakening. The patients will be allocated to zero PEEP (ZEEP) or maintained PEEP during emergence preoxygenation and extubation. Importantly, the intervention group will have ZEEP established while still having low ETO2 levels, prior to any preoxygenation. Arterial blood gases will be collected before, during and after anaesthesia. Primary endpoint measure will be change in oxygenation from before awakening to after awakening.

Eligibility Criteria:
Inclusion Criteria:

* Obese patients scheduled for elective laparocopic surgery.
* American Society of Anesthesiologists functional class I-III
* Body Mass Index 35-50 kg/m2

Exclusion Criteria:

* Body Mass Index ≥50 kg/m2
* Peripheral oxygen saturation (SpO2) breathing air \<94 %
* Symtomatic asthma, COPD or heart failure
* Ischemic heart disease
* Hemoglobin \< 100g/l
* Smokers and ex-smokers that stopped smoking \< 9 months ago
* Need for peroperative RM and PEEP higher than in study protocol, as indicated by SpO2 \<92% despite the stipulated FiO2 0.30-0.35.
* Obstructive sleep apnea syndrome on home-CPAP
tDCS and Robotic Training in Adults With Cerebral Palsy

The purpose of this study is to improve arm function in adults with hemiplegic cerebral palsy. Participants will receive transcranial direct current stimulation (or sham) in combination with upper extremity robotic therapy.

Therapy consists of 20 minutes of non-invasive, low-level brain stimulation (transcranial direct current stimulation, tDCS), followed by one hour of shoulder/wrist robotic training. Participants will be enrolled in therapy 3 times per week for 12 weeks (or 36 sessions). Before and after therapy, participants will receive and assessment of their arm function, as well as an assessment of their brain activity, using electroencephalography (EEG) and transcranial magnetic stimulation (TMS).

Eligibility Criteria:
Inclusion Criteria:

* Participant willing and able to provide informed consent
* Diagnosis of hemiplegic Cerebral Palsy
* Joint mobility: wrist extention (20 degrees), metacarophalangeal and proximal interphalangeal joints (10 degrees)

Exclusion Criteria:

* Cognitive deficits that impede understanding of study protocol
* Current medical illness unrelated to CP
* Visual problems (uncorrected by glasses/contact lenses)
* High motor ability in affected arm
* Severe spasticity
* Lack of asymmetry in hand function
* Orthopedic surgery in affected arm within 2 years
* Dorsal root rhizotomy
* Botulinum toxin therapy in either upper extremity during last 2 months, or planned during study period
* Currently receiving intrathecal baclofen
* Seizure beyond age 2, use of anti-seizure medication, history of epilepsy (in self or first degree relatives), brain surgery, cranial metal implants, structural brain lesion, deices that may be affected by TMS (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
* True positive response on the Transcranial Magnetic Stimulation Safety Screen
* Current use of medications known to lower the seizure threshold
* Previous episode of neurocardiogenic snycopy
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer

The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens for use in assessing new biomarkers for the detection of neoplasms of the lung. Subjects will be men and women, 35 years of age and older, with a CT confirmed nodule measuring 6-30 mm.

Subjects with pulmonary nodules, a suspicion of lung cancer or pathologically confirmed, untreated lung cancer will be enrolled. Blood samples will be collected at enrollment and may be collected at 12 months for subjects with pulmonary nodules. Radiological and pathological data will be collected to confirm a cancer diagnosis or up to 2 years to assess nodule resolution.

Eligibility Criteria:
Inclusion Criteria:

* All Subjects:

  1. Subject is male or female, 35 years of age or older.
  2. Subject has at least one CT confirmed 6-30 mm nodule.
  3. Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

     Suspicion of Cancer Subjects:
  4. Subject has CT suspicion of lung cancer and is scheduled for biopsy or other diagnostic procedure.

Pathologically Confirmed Cancer Subjects:

4. Subject has pathologically confirmed lung cancer and is treatment naïve.

Pulmonary Nodule Subjects:

4. Subject has a recent (within 90 days of enrollment) CT radiological diagnosis of pulmonary nodule(s) without a scheduled biopsy/diagnostic procedure (other than CT or PET/CT).

Exclusion Criteria:

* All Subjects

  1. CT with IV contrast within 1 day \[or 24 hours\] of blood collection.
  2. Prior history of cancer within the past 5 years except for non-melanoma skin cancer. For subjects with suspicion of lung cancer who may have a concurrent work-up for another primary cancer, the non-lung cancer primary must be ruled out prior to enrollment.
  3. Prior removal of the lung, excluding percutaneous lung biopsy.
  4. Treatment (e.g., surgical resection, radiofrequency ablation) for pulmonary nodules prior to blood sample collection for this trial.
  5. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

     Pathologically Confirmed Cancer Subjects:
  6. Biopsy within 7 days prior to blood collection.
  7. Unresolved bleeding as a result of biopsy at the time of enrollment.
A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in at least one eye.

Exclusion Criteria:

* Pregnant or nursing females.
* Use of any antibiotic within 72 hours of enrollment.
* Any disease conditions that could interfere with the safety and efficacy evaluations of the study drug.
* Participation in an ophthalmic drug or device research study within 30 days prior to entry into this study.
Feasibility Testing of a Hospice Family Caregiver Intervention to Improve Patient Dyspnea Care

This study is a pilot test of an intervention to train family caregivers of home hospice patients about recognizing and treating shortness of breath.

Shortness of breath is a prevalent symptom causing distress among patients at the end of life. In home hospice care family caregivers are expected to assist their family member with symptom management. This is often accomplished with little or no training.

The investigators have developed a bundle of training materials targeted for family caregivers of home hospice patients at risk for shortness of breath. The investigators will pilot test the intervention in this clinical trial. A future randomized clinical trial is planned and the evidence from this pilot will enhance the planning of that future trial.

Eligibility Criteria:
Inclusion Criteria:

* Patient in home hospice care with an estimated survival of 3-4 weeks, at risk for dyspnea secondary to lung cancer, COPD, or heart failure.
* Family caregiver in patient's home must speak and read English.

Exclusion Criteria:

* Patients with bulbar ALS or quadriplegia.
The Impact of Pulmonary Rehabilitation in Interstitial Lung Disease

The purpose of this study is to determine if pulmonary rehabilitation has any effect on breathlessness, quality of life, physical function and depression in persons with interstitial lung disease.


Eligibility Criteria:
Inclusion Criteria:

* Adults (\> 18 years old) with a diagnosis of ILD who are referred to a participating PR program

Exclusion Criteria:

* Inability to provide informed consent
* Inability to read and write English
* Any other medical condition that significantly limits the subject's ability to perform the functional measures
* Emphysema / Chronic bronchitis (FEV1 / FVC ratio \< 60%)
* Previous pulmonary rehabilitation